← Oncology Approval Tracker

FDA DECISION ·

Cabometyx

cabozantinib · Exelixis

FDA approvalNew or expanded indicationThyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients age 12 and older with locally advanced or metastatic differentiated thyroid cancer that progressed after a VEGFR-directed therapy, when radioactive iodine is ineffective or inappropriate.

LAMPGEN ANALYSIS

Why it matters

The decision adds a later-line option for differentiated thyroid cancer after VEGFR inhibition.

What research teams should watch

Check age, thyroid histology, progression on prior treatment and the radioactive iodine history.

PRIMARY RECORDS

Sources